$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000162828017004968 Filed on May 04, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$235.0K	$603.0K
YoY Change	-61.03%	-87.12%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.330M	$7.220M
YoY Change	-40.03%	165.44%
% of Gross Profit
Research & Development	$13.87M	$13.14M
YoY Change	5.54%	24.51%
% of Gross Profit
Depreciation & Amortization	$334.0K	$217.0K
YoY Change	53.92%	80.83%
% of Gross Profit
Operating Expenses	$18.53M	$20.58M
YoY Change	-9.94%	-9.29%
Operating Profit	-$18.30M	-$19.98M
YoY Change	-8.4%	10.95%
Interest Expense	$42.00K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$328.0K	$4.103M
YoY Change	-107.99%	-31.81%
Pretax Income	-$18.63M	-$15.87M
YoY Change	17.39%	32.36%
Income Tax
% Of Pretax Income
Net Earnings	-$18.63M	-$15.87M
YoY Change	17.34%	32.4%
Net Earnings / Revenue	-7926.38%	-2632.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$343.0K	-$308.8K
COMMON SHARES
Basic Shares Outstanding	55.02M shares	54.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$110.4M	$172.6M
YoY Change	-36.04%	-25.7%
Cash & Equivalents	$29.85M	$144.8M
Short-Term Investments	$80.50M	$27.80M
Other Short-Term Assets	$1.600M	$1.500M
YoY Change	6.67%	15.38%
Inventory
Prepaid Expenses
Receivables	$7.878M	$340.0K
Other Receivables	$300.0K	$200.0K
Total Short-Term Assets	$120.3M	$174.8M
YoY Change	-31.18%	-27.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.46M	$3.242M
YoY Change	253.55%	80.11%
Goodwill	$24.36M	$162.5M
YoY Change	-85.01%
Intangibles	$99.45M	$352.6M
YoY Change	-71.8%
Long-Term Investments		$10.10M
YoY Change
Other Assets	$12.60M
YoY Change
Total Long-Term Assets	$147.9M	$528.5M
YoY Change	-72.02%	-3.44%
TOTAL ASSETS
Total Short-Term Assets	$120.3M	$174.8M
Total Long-Term Assets	$147.9M	$528.5M
Total Assets	$268.1M	$703.3M
YoY Change	-61.87%	-10.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.600M	$4.000M
YoY Change	-60.0%	-44.44%
Accrued Expenses	$5.300M	$3.400M
YoY Change	55.88%	-46.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.87M	$11.11M
YoY Change	-2.17%	-55.37%
LONG-TERM LIABILITIES
Long-Term Debt	$12.00M	$0.00
YoY Change
Other Long-Term Liabilities	$14.90M	$7.700M
YoY Change	93.51%	-38.89%
Total Long-Term Liabilities	$26.90M	$7.700M
YoY Change	249.35%	-38.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.87M	$11.11M
Total Long-Term Liabilities	$26.90M	$7.700M
Total Liabilities	$79.04M	$165.2M
YoY Change	-52.15%	-14.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$669.8M	-$282.9M
YoY Change	136.79%
Common Stock	$870.8M	$840.5M
YoY Change	3.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$189.1M	$538.1M
YoY Change
Total Liabilities & Shareholders Equity	$268.1M	$703.3M
YoY Change	-61.87%	-10.65%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$18.63M	-$15.87M
YoY Change	17.34%	32.4%
Depreciation, Depletion And Amortization	$334.0K	$217.0K
YoY Change	53.92%	80.83%
Cash From Operating Activities	-$17.54M	-$11.55M
YoY Change	51.87%	-35.29%
INVESTING ACTIVITIES
Capital Expenditures	$3.423M	$276.0K
YoY Change	1140.22%	95.74%
Acquisitions
YoY Change
Other Investing Activities	$26.62M	-$13.31M
YoY Change	-300.0%	-135.31%
Cash From Investing Activities	$23.20M	-$13.58M
YoY Change	-270.78%	-136.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$354.0K	$115.0K
YoY Change	207.83%	-99.92%
NET CHANGE
Cash From Operating Activities	-$17.54M	-$11.55M
Cash From Investing Activities	$23.20M	-$13.58M
Cash From Financing Activities	$354.0K	$115.0K
Net Change In Cash	$6.014M	-$25.01M
YoY Change	-124.04%	-115.39%
FREE CASH FLOW
Cash From Operating Activities	-$17.54M	-$11.55M
Capital Expenditures	$3.423M	$276.0K
Free Cash Flow	-$20.96M	-$11.82M
YoY Change	77.28%	-34.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	abus	Accrued License Fee Accruals AccruedLicenseFeeAccruals	0	USD
CY2017Q1	abus	Accrued License Fee Accruals AccruedLicenseFeeAccruals	48000	USD
CY2016Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2178000	USD
CY2017Q1	abus	Accrued Payroll Current AccruedPayrollCurrent	214000	USD
CY2016Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	3131000	USD
CY2017Q1	abus	Accrued Research And Development AccruedResearchAndDevelopment	2856000	USD
CY2017Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-190000	USD
CY2017Q1	abus	Classof Warrantor Rights Expired ClassofWarrantorRightsExpired	22000	shares
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2781000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
CY2016Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	553000	USD
CY2017Q1	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	819000	USD
CY2016Q4	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	553000	USD
CY2017Q1	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	819000	USD
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2017Q1	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	129000	USD
CY2016Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	244000	USD
CY2017Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	1059000	USD
CY2016Q1	abus	Warrants Exercised WarrantsExercised	0	shares
CY2017Q1	abus	Warrants Exercised WarrantsExercised	179000	shares
CY2017Q1	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	22000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9330000	CAD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2016Q1	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	1000000	USD
CY2017Q1	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2016	abus	Restricted Investment Term RestrictedInvestmentTerm	P2Y
CY2017Q1	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55024557	shares
CY2017Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9910000	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7428000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3215000	USD
CY2017Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1614000	USD
CY2016Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	273000	USD
CY2017Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	7878000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	273000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7878000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	498000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	514000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10738000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11061000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	36543000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	37809000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4428000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7371193	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5961443	shares
CY2016Q4	us-gaap	Assets Assets	275919000	USD
CY2017Q1	us-gaap	Assets Assets	268140000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	132564000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	120268000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	143160000	USD
CY2017Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	122980000	USD
CY2016Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	244000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1059000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9065000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10124000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1427000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166779000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144772000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23413000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29851000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	23413000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	29851000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-22007000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6438000	USD
CY2016Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2017Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54841494	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55024545	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54841494	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55024545	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	867393000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	870847000	USD
CY2016Q1	us-gaap	Contracts Revenue ContractsRevenue	107000	USD
CY2017Q1	us-gaap	Contracts Revenue ContractsRevenue	18000	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	15000	USD
CY2017Q1	us-gaap	Deferred Revenue DeferredRevenue	7407000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2624000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4783000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	41263000	USD
CY2017Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	41263000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	217000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	334000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3006000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	424000	USD
CY2016Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	161000	USD
CY2017Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22000	USD
CY2016Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2942000	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	427000	USD
CY2016Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	3006000	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	425000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7219000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4328000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	24364000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	24364000	USD
CY2016Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	293000	USD
CY2017Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	308000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1116000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3909000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-668000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7605000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-157000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7392000	USD
CY2016Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2017Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	15000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	273000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	264000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	99445000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	99445000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	42000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	244000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	368000	USD
CY2016Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	107146000	USD
CY2017Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	80528000	USD
CY2016Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	350000	USD
CY2017Q1	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	465000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	72914000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	79042000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275919000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	268140000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10585000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10871000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	9725000	USD
CY2017Q1	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	10943000	USD
CY2016Q1	us-gaap	Licenses Revenue LicensesRevenue	496000	USD
CY2017Q1	us-gaap	Licenses Revenue LicensesRevenue	217000	USD
CY2016Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	12001000	USD
CY2017Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	12001000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	115000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17535000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-15874000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-18627000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4103000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-328000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	20580000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	18534000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19977000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18299000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	538000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1717000	USD
CY2016Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	13306000	USD
CY2017Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-26618000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	354000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13582000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23195000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11546000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	276000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3423000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1311000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1575000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	115000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
CY2016Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	353000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17683000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22523000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6945000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11462000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13144000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13872000	USD
CY2016Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	12601000	USD
CY2017Q1	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	12601000	USD
CY2016Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2017Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-651149000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-669776000	USD
CY2016Q1	us-gaap	Revenues Revenues	603000	USD
CY2017Q1	us-gaap	Revenues Revenues	235000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	107146000	USD
CY2017Q1	us-gaap	Short Term Investments ShortTermInvestments	80528000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	481000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	203005000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	189098000	USD
CY2016Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2017Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	107000	USD
CY2017Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2016Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	107000	USD
CY2017Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	0	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	51400485	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54307464	shares
CY2017Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). The Company's portfolio of assets includes a broad pipeline of drug candidates to develop a cure for HBV and leverages the Company’s expertise in Lipid Nanoparticle ("LNP") technology.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company’s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-004968-index-headers.html	Edgar Link	pending
0001628280-17-004968-index.html	Edgar Link	pending
0001628280-17-004968.txt	Edgar Link	pending
0001628280-17-004968-xbrl.zip	Edgar Link	pending
abus-20170331.xml	Edgar Link	completed
abus-20170331.xsd	Edgar Link	pending
abus-20170331_cal.xml	Edgar Link	unprocessable
abus-20170331_def.xml	Edgar Link	unprocessable
abus-20170331_lab.xml	Edgar Link	unprocessable
abus-20170331_pre.xml	Edgar Link	unprocessable
arbutusq12017.htm	Edgar Link	pending
exhibit311q12017.htm	Edgar Link	pending
exhibit312q12017.htm	Edgar Link	pending
exhibit321q12017.htm	Edgar Link	pending
exhibit322q12017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
q12017pipeline2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2017 Q1 Form 10-Q Financial Statement

#000162828017004968 Filed on May 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2017 Q1 Form 10-Q Financial Statement

#000162828017004968 Filed on May 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus